There are 2867 resources available
1168P - Effect of antibiotic treatment on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer
Presenter: Gulin Alkan
Session: Poster session 16
1169P - Aggregated cancer registry data from Norway to create an external cohort for patients with metastatic NSCLC squamous cell carcinoma
Presenter: Siri Børø
Session: Poster session 16
1170P - Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)
Presenter: Benjamin Besse
Session: Poster session 16
1171P - A phase II theranostic study with osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitors (TKI) and undetectable EGFR T790M (THEROS)
Presenter: Marcel Wiesweg
Session: Poster session 16
1172P - High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC)
Presenter: Xiuning Le
Session: Poster session 16
1173P - Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study
Presenter: Byoung Chul Cho
Session: Poster session 16
1175P - Pharmacokinetics of ensartinib in advanced solid tumors and anaplastic lymphoma kinase-positive non-small cell lung cancer
Presenter: Yan Xu
Session: Poster session 16
1176P - Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)
Presenter: Johan Vansteenkiste
Session: Poster session 16
1177P - Clinical implications of TSC1/TSC2 variants on immunotherapy in NSCLC patients
Presenter: Lijuan Chen
Session: Poster session 16